Full-Time

Sr. Manager

Drug Product

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$176k - $190kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position based in San Carlos, California.

Category
QA & Testing
Quality Assurance
Requirements
  • Bachelor’s degree in Biochemistry, Chemistry, or a related field with 9+ years of relevant industry experience.
  • Thorough knowledge of applicable FDA, EU, and ICH regulatory guidelines and pharmacopeia for method qualification and validation in biologics and vaccines, along with proven expertise in applying these regulations to develop practical solutions and phase-appropriate analytical strategies.
  • Experience working with biochemistry, immunoassay, or microbiological assay techniques.
  • Excellent organizational and project management skills, with the ability to handle multiple projects under tight timelines.
  • Strong written and verbal communication skills, including the ability to work effectively in cross-functional teams.
  • Previous experience in validation and transfer of analytical assays is highly desired.
  • Ability to integrate and interpret interdisciplinary project information; with at least a high-level understanding of the drug/vaccine development process.
  • Ability to work globally with CMOs in different countries and continents.
  • Ability to work in a fast-paced, cross-functional environment and collaborate effectively with other team members.
  • Experience in IND, NDA, and BLA submission is preferred.
Responsibilities
  • Review validation and transfer protocols, data, and reports for analytical assays associated with the PCV drug product program. Collaborate with Quality Control to set appropriate validation/transfer acceptance criteria.
  • Act as the main contact within Vaxcyte QA and with external partners, fostering collaborations to support analytical requirements for Vaxcyte's PCV Drug Product programs. Work with internal stakeholders to understand methods performed onsite and at CMOs.
  • Review test methods, protocols, data, and CoAs from CMOs with technical and compliance expertise. Give compliance feedback to stakeholders who have developed the analytical methods.
  • Review and manage deviations, OOS/OOT results, and perform risk assessments related to drug product testing. Support vendor management for drug product testing vendors. Act as the Analytical QA representative in internal drug product discussions.
  • Accountable for execution and oversight of processes within the quality system as they apply to PCV drug product (deviations and investigations, change controls, and CAPAs).
  • Support regulatory submissions and responses to health authority questions during various clinical phase filings.
  • Work with others to identify opportunities for continuous improvement and implement/maintain solutions.
  • Provide strong teamwork in establishing a quality culture and shared accountability.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

19%

1 year growth

61%

2 year growth

129%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?